Literature DB >> 15580295

Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth.

Eran R Andrechek1, Donald White, William J Muller.   

Abstract

The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580295     DOI: 10.1038/sj.onc.1208230

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

Review 1.  Hormonal and local control of mammary branching morphogenesis.

Authors:  Mark D Sternlicht; Hosein Kouros-Mehr; Pengfei Lu; Zena Werb
Journal:  Differentiation       Date:  2006-09       Impact factor: 3.880

Review 2.  Integrated morphodynamic signalling of the mammary gland.

Authors:  Nikolce Gjorevski; Celeste M Nelson
Journal:  Nat Rev Mol Cell Biol       Date:  2011-08-10       Impact factor: 94.444

Review 3.  ErbB/EGF signaling and EMT in mammary development and breast cancer.

Authors:  Katharine M Hardy; Brian W Booth; Mary J C Hendrix; David S Salomon; Luigi Strizzi
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-04-06       Impact factor: 2.673

4.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue.

Authors:  Lejla Pasic; T S Karin Eisinger-Mathason; Bisi T Velayudhan; Christopher A Moskaluk; David R Brenin; Ian G Macara; Deborah A Lannigan
Journal:  Genes Dev       Date:  2011-08-01       Impact factor: 11.361

Review 5.  Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Int J Cancer       Date:  2016-09-12       Impact factor: 7.396

6.  Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin.

Authors:  Mark D Sternlicht; Susan W Sunnarborg; Hosein Kouros-Mehr; Ying Yu; David C Lee; Zena Werb
Journal:  Development       Date:  2005-08-03       Impact factor: 6.868

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 8.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

Review 9.  The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.

Authors:  Mark D Sternlicht; Susan W Sunnarborg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-10       Impact factor: 2.673

10.  LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Authors:  M E Montañez-Wiscovich; D D Seachrist; M D Landis; J Visvader; B Andersen; R A Keri
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.